{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=GI+Carcinoma&page=2", "query": { "condition": "GI Carcinoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=GI+Carcinoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-24T07:12:25.851Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06690281", "title": "A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastrointestinal Carcinoma", "Pancreatic Cancer", "Hepatocellular Cancer", "Cholangiocarcinoma", "Duodenal Cancer", "Colorectal Cancer", "Small Bowel Cancer", "Metastatic Cancers" ], "interventions": [ { "name": "KRAS TCR-Transduced PBL", "type": "BIOLOGICAL" }, { "name": "Aldesleukin", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "72 Years", "sex": "ALL", "summary": "18 Years to 72 Years" }, "enrollment_count": 0, "start_date": "2025-09-09", "completion_date": "2025-09-09", "has_results": false, "last_update_posted_date": "2025-09-11", "last_synced_at": "2026-09-24T07:12:25.851Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06690281" }, { "nct_id": "NCT00767234", "title": "Permission to Collect Blood Over Time for Research", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pancreatic Cancer", "Gastrointestinal Neoplasms", "Colon Rectal Cancer Adenocarcinoma", "Esophageal Cancer", "Gall Bladder Cancer", "Gastric (Stomach) Cancer", "Gastrooesophageal Cancer", "Gastrointestinal Stromal Tumor (GIST)", "Hepatobiliary Neoplasm", "Liver Carcinoma", "Gallbladder Carcinoma", "Bile Duct Carcinoma", "Carcinoma of the Large Intestine", "Anal Cancer" ], "interventions": [ { "name": "Observation", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 104, "start_date": "2008-08", "completion_date": "2011-10", "has_results": false, "last_update_posted_date": "2016-07-11", "last_synced_at": "2026-09-24T07:12:25.851Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00767234" }, { "nct_id": "NCT01420874", "title": "Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Cancer of Pancreas", "Pancreatic Neoplasm", "Malignant Neoplasm of Large Intestine", "Malignant Tumor of Colon", "Colon Carcinoma", "Cancer of Colon", "Pancreatic Cancer" ], "interventions": [ { "name": "FOLFOX6", "type": "DRUG" }, { "name": "EGFRBi armed ATC Infusions", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2011-08-17", "completion_date": "2020-10-19", "has_results": false, "last_update_posted_date": "2023-05-06", "last_synced_at": "2026-09-24T07:12:25.851Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01420874" }, { "nct_id": "NCT06414733", "title": "HER-2 B Cell Peptide Vaccine", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Breast Cancer", "HER2-positive Breast Cancer", "EGFR Overexpression", "Metastatic Esophageal Carcinoma", "HER-2 Positive Esophageal Cancer" ], "interventions": [ { "name": "Combination of MVF-HER-2 (597-626) and MVF-HER-2 (266-296) emulsified with ISA 51", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pravin T.P Kaumaya", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2025-01-17", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-09-24T07:12:25.851Z", "location_count": 1, "location_summary": "Indianpolis, Indiana", "locations": [ { "city": "Indianpolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT06414733" }, { "nct_id": "NCT02751879", "title": "Real World Data on Gi(l)Otrif® Dose Adjustment", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [], "intervention_types": [], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 228, "start_date": "2016-11-24", "completion_date": "2017-09-30", "has_results": true, "last_update_posted_date": "2019-08-08", "last_synced_at": "2026-09-24T07:12:25.851Z", "location_count": 2, "location_summary": "The Bronx, New York • Charlotte, North Carolina", "locations": [ { "city": "The Bronx", "state": "New York" }, { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02751879" }, { "nct_id": "NCT04197310", "title": "Cabozantinib and Nivolumab for Carcinoid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoid Tumor", "Carcinoid Tumor of GI System", "Neuroendocrine Tumors" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Cabozantinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2019-12-26", "completion_date": "2024-01-31", "has_results": true, "last_update_posted_date": "2025-01-31", "last_synced_at": "2026-09-24T07:12:25.851Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04197310" }, { "nct_id": "NCT05482516", "title": "Evaluating Novel Therapies in ctDNA Positive GI Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colon Adenocarcinoma", "Rectal Adenocarcinoma", "Gastric Adenocarcinoma", "Pancreatic Adenocarcinoma", "Hepatocellular Carcinoma", "Adenocarcinoma of Biliary Tract", "Gallbladder Adenocarcinoma" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2023-03-29", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-09-24T07:12:25.851Z", "location_count": 3, "location_summary": "Washington D.C., District of Columbia • Hackensack, New Jersey", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05482516" }, { "nct_id": "NCT04596384", "title": "Home Base Telemonitoring in Gastrointestinal, Genitourinary, or Gynecologic Cancer Patients Undergoing Abdominal Surgery", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Digestive System Carcinoma", "Genitourinary System Carcinoma", "Malignant Female Reproductive System Neoplasm", "Malignant Solid Neoplasm" ], "interventions": [ { "name": "Best Practice", "type": "OTHER" }, { "name": "Functional Assessment", "type": "PROCEDURE" }, { "name": "Medical Device Usage and Evaluation", "type": "OTHER" }, { "name": "Nutritional Assessment", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "TapCloud", "type": "OTHER" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 398, "start_date": "2021-02-16", "completion_date": "2026-11-30", "has_results": true, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-09-24T07:12:25.851Z", "location_count": 3, "location_summary": "Duarte, California • Lancaster, California • South Pasadena, California", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "South Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04596384" }, { "nct_id": "NCT02649569", "title": "Continuous Activity Monitoring During Fractionated Radiotherapy in Patients With Head and Neck, Lung, or Gastrointestinal Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Digestive System Carcinoma", "Head and Neck Carcinoma", "Lung Carcinoma" ], "interventions": [ { "name": "Monitoring Device", "type": "DEVICE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "DEVICE", "OTHER" ], "sponsor": "Montefiore Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2015-06", "completion_date": "2017-07", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-09-24T07:12:25.851Z", "location_count": 2, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02649569" }, { "nct_id": "NCT03929666", "title": "A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer" ], "interventions": [ { "name": "ZW25 (Zanidatamab)", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jazz Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 74, "start_date": "2019-08-29", "completion_date": "2025-08-30", "has_results": false, "last_update_posted_date": "2025-09-12", "last_synced_at": "2026-09-24T07:12:25.851Z", "location_count": 11, "location_summary": "Los Angeles, California • Newport Beach, California • Tampa, Florida + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03929666" } ] }